While many activities within IASLC are ongoing, the last month has notably been a success for IASLC in Asia. A very successful IASLC workshop on personalized therapy in lung cancer was held in Shanghai under the leadership of Professor Caicun Zhou, and a few weeks ago the Chinese Society of Clinical Oncology (CSCO) held its Annual Meeting with more than 20,000 participants. The program included an IASLC/CSCO session on molecular targeted-therapies in NSCLC. Thanks to Professor Yi-Long Wu, who is now also President of CSCO, and to the IASLC President Professor Tony Mok, who is now also vice-president of CSCO, for establishing this very exciting session at CSCO. The IASLC/CSCO session drew a fully packed audience.
Tony S.K. Mok, IASLC President
Pleasant surprises awaited me at the end of an eighteen hours journey. It was home, a very lovely home. However, it was not my home but the home of IASLC. This is the first time in the history of our organization that the Board of Directors meeting took place at our home office. Not sure if I can find the right words to label my emotion when I saw the brilliant “IASLC” logo at the office entrance. This cozy office is actually the united front of scientists, doctors, nurses and patients in the war against lung cancer. This is the physical facility that represents our fighting spirit.
Education in lung cancer management for doctors in community practices is of high priority for IASLC. I am proud to tell that IASLC has recently made a joint project partnership with American College of Chest Physicians (ACCP) to develop educational “class room” programs in diagnosis and management of patients with lung cancer, which will include programs in the US and Europe. IASLC is very proud of this collaborative effort, and the first summit will be held in the US this fall.
Personalized medicine is a popular term but yet its success doesn’t come easy. Over the past decade we had successfully established EGFR mutation and ALK mutation as the prime target for personalized medicine. The key ingredients to successful formula of personalize therapy for lung cancer would include driver oncogene, biomarker and established efficacy in the biomarker-selected population ( and lack of such in the biomarker-negative population).